Skip to main content

NYSE:IMAX - IMAX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.05
  • Forecasted Upside: 14.31 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$21.04
▲ +0.12 (0.57%)
1 month | 3 months | 12 months
Get New IMAX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMAX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$24.05
▲ +14.31% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for IMAX in the last 3 months. The average price target is $24.05, with a high forecast of $30.00 and a low forecast of $14.50. The average price target represents a 14.31% upside from the last price of $21.04.

Buy

The current consensus among 8 polled investment analysts is to buy stock in IMAX. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2021MacquarieBoost Price TargetOutperform$25.00 ➝ $30.00High
i
4/29/2021WedbushUpgradeNeutral ➝ Outperform$22.00 ➝ $26.00N/A
i
Rating by M. Pachter at Wedbush
4/23/2021WedbushUpgradeNeutral ➝ Outperform$22.00 ➝ $26.00Low
i
Rating by M. Pachter at Wedbush
3/16/2021B. RileyReiterated RatingBuy$28.00High
i
3/9/2021Barrington ResearchBoost Price Target$25.00 ➝ $27.00Low
i
3/5/2021MacquarieBoost Price TargetPositive ➝ Outperform$24.00 ➝ $25.00High
i
3/5/2021BenchmarkBoost Price TargetHold ➝ Buy$22.00 ➝ $24.00High
i
3/1/2021WedbushBoost Price TargetNeutral$14.00 ➝ $22.00Low
i
2/1/2021MKM PartnersBoost Price TargetBuy$18.00 ➝ $25.00Low
i
1/26/2021B. RileyBoost Price TargetUnderperform$26.00 ➝ $28.00High
i
1/25/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$15.60 ➝ $17.90High
i
12/29/2020B. RileyBoost Price TargetPositive ➝ Buy$18.00 ➝ $26.00N/A
i
Rating by Eric Wold at B. Riley
12/21/2020B. RileyReiterated RatingBuy$18.00Low
i
Rating by Eric Wold at B. Riley
10/12/2020B. RileyLower Price Target$21.00 ➝ $18.00High
i
Rating by Eric Wold at B. Riley
9/4/2020B. RileyBoost Price Target$18.00 ➝ $21.00Low
i
Rating by Eric Wold at B. Riley
9/2/2020Barrington ResearchBoost Price TargetOutperform$15.00 ➝ $18.00Medium
i
Rating by J. Goss at Barrington Research
9/1/2020The Goldman Sachs GroupBoost Price Target$14.00 ➝ $16.00Low
i
7/29/2020Barrington ResearchReiterated RatingBuy$15.00High
i
Rating by J. Goss at Barrington Research
7/29/2020Canaccord GenuityReiterated RatingIn-Line ➝ Buy$16.00 ➝ $14.50High
i
7/29/2020B. RileyReiterated RatingBuy$18.00High
i
Rating by Eric Wold at B. Riley
7/24/2020WedbushInitiated CoverageHold$14.00Low
i
Rating by Michael Pachter at Wedbush
7/20/2020Barrington ResearchReiterated RatingOutperformHigh
i
Rating by J. Goss at Barrington Research
7/16/2020B. RileyReiterated RatingBuy$18.00High
i
Rating by Eric Wold at B. Riley
7/15/2020The Goldman Sachs GroupInitiated CoverageBuy$14.00High
i
7/13/2020MKM PartnersLower Price TargetBuy$20.00 ➝ $18.00High
i
5/1/2020Canaccord GenuityReiterated RatingBuy$16.00High
i
Rating by Aravinda Galappatthige at Canaccord Genuity
5/1/2020B. RileyReiterated RatingBuy$19.00Low
i
Rating by Eric Wold at B. Riley
4/30/2020Barrington ResearchReiterated RatingBuy$15.00Low
i
Rating by James Goss at Barrington Research
4/28/2020BenchmarkUpgradeHold ➝ Buy$14.00High
i
4/24/2020WedbushDowngradeOutperform ➝ Neutral$25.00 ➝ $12.00Low
i
Rating by M. Pachter at Wedbush
4/15/2020MKM PartnersLower Price TargetBuy$24.00 ➝ $20.00Medium
i
Rating by Eric Handler at MKM Partners
4/2/2020B. RileyReiterated RatingBuy$19.00High
i
Rating by Eric Wold at B. Riley
3/24/2020Barrington ResearchReiterated RatingOutperform$20.00 ➝ $15.00High
i
Rating by James Goss at Barrington Research
3/18/2020B. RileyLower Price TargetBuy$26.00 ➝ $19.00High
i
Rating by Eric Wold at B. Riley
3/17/2020BenchmarkDowngradeBuy ➝ HoldHigh
i
3/17/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$22.00 ➝ $15.00High
i
2/24/2020Barrington ResearchLower Price TargetOutperform$24.00 ➝ $20.00High
i
2/20/2020WedbushBoost Price TargetOutperform$22.00 ➝ $25.00High
i
Rating by M. Pachter at Wedbush
2/20/2020Canaccord GenuityUpgradeBuy$23.00High
i
Rating by Aravinda Galappatthige at Canaccord Genuity
2/12/2020B. RileyReiterated RatingBuy$30.00 ➝ $26.00Low
i
Rating by Eric Wold at B. Riley
2/4/2020MKM PartnersLower Price TargetBuy$24.00High
i
Rating by Eric Handler at MKM Partners
2/3/2020WedbushReiterated RatingOutperform$28.00 ➝ $22.00Low
i
Rating by Michael Pachter at Wedbush
1/29/2020BenchmarkLower Price TargetBuy$28.00 ➝ $20.00High
i
12/5/2019B. RileyReiterated RatingBuy$30.00Low
i
Rating by Eric Wold at B. Riley
11/19/2019MKM PartnersReiterated RatingBuy$28.00Low
i
Rating by Eric Handler at MKM Partners
11/1/2019WedbushReiterated RatingHold ➝ Buy$28.00Low
i
Rating by Michael Pachter at Wedbush
11/1/2019Canaccord GenuityUpgradeHold ➝ Buy$25.00Medium
i
10/21/2019WedbushSet Price TargetBuy$28.00Low
i
Rating by Michael Pachter at Wedbush
10/15/2019The Goldman Sachs GroupSet Price TargetHold$23.00Low
i
Rating by Drew Borst at The Goldman Sachs Group, Inc.
9/10/2019B. RileySet Price TargetBuy$34.00High
i
Rating by Eric Wold at B. Riley
7/31/2019WedbushReiterated RatingOutperform$28.00Low
i
Rating by Michael Pachter at Wedbush
7/16/2019WedbushReiterated RatingBuy$28.00Low
i
Rating by Michael Pachter at Wedbush
7/12/2019B. RileySet Price TargetBuy$34.00Low
i
Rating by Eric Wold at B. Riley
5/20/2019B. RileySet Price TargetBuy$34.00Low
i
Rating by Eric Wold at B. Riley
4/26/2019B. RileySet Price TargetBuy$34.00Low
i
Rating by Eric Wold at B. Riley
4/22/2019WedbushSet Price TargetBuy$28.00Medium
i
Rating by M. Pachter at Wedbush
4/12/2019MKM PartnersBoost Price TargetBuy$28.00Low
i
4/8/2019B. RileySet Price TargetBuy$34.00Low
i
Rating by Eric Wold at B. Riley
3/6/2019Barrington ResearchReiterated RatingBuy$27.00Low
i
2/25/2019Canaccord GenuityDowngradeBuy ➝ Hold$23.00High
i
Rating by Aravinda Galappatthige at Canaccord Genuity
2/22/2019WedbushReiterated RatingOutperform$28.00Medium
i
Rating by M. Pachter at Wedbush
1/30/2019WedbushReiterated RatingOutperformLow
i
Rating by M. Pachter at Wedbush
1/2/2019B. RileySet Price TargetBuy$34.00Low
i
Rating by Eric Wold at B. Riley
12/24/2018B. RileySet Price TargetBuy IMAX$34.00High
i
Rating by Eric Wold at B. Riley
12/7/2018B. RileySet Price TargetBuy$34.00Low
i
Rating by Eric Wold at B. Riley
10/29/2018Barrington ResearchLower Price TargetOutperform$27.00Low
i
10/26/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$26.00 ➝ $23.00High
i
Rating by Aravinda Galappatthige at Canaccord Genuity
10/15/2018WedbushSet Price TargetBuy$29.00Low
i
Rating by Michael Pachter at Wedbush
7/26/2018WedbushSet Price TargetBuy$32.00High
i
Rating by Michael Pachter at Wedbush
7/3/2018WedbushReiterated RatingBuy$32.00Low
i
Rating by Michael Pachter at Wedbush
5/2/2018B. RileyLower Price TargetBuy ➝ Buy$37.75 ➝ $34.00Medium
i
4/27/2018WedbushSet Price TargetBuy$32.00Low
i
Rating by Michael Pachter at Wedbush
4/27/2018BenchmarkUpgradeHold ➝ Buy$28.00Low
i
4/25/2018Canaccord GenuitySet Price TargetBuy$26.00Medium
i
Rating by Aravinda Galappatthige at Canaccord Genuity
4/9/2018WedbushSet Price TargetBuy$32.00Medium
i
Rating by Michael Pachter at Wedbush
3/20/2018Barrington ResearchReiterated RatingBuy$30.00Medium
i
2/28/2018Roth CapitalReiterated RatingBuy ➝ Neutral$25.00 ➝ $22.50High
i
Rating by D. Aftahi at Roth Capital
2/28/2018B. RileyBoost Price TargetBuy ➝ Buy$35.00 ➝ $37.75High
i
2/20/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$27.00 ➝ $28.00Medium
i
Rating by Julia Yue at JPMorgan Chase & Co.
2/20/2018WedbushSet Price TargetOutperform$30.00Medium
i
Rating by Michael Pachter at Wedbush
1/10/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$28.00 ➝ $21.00Low
i
1/8/2018B. RileyReiterated RatingBuy$35.00High
i
1/8/2018WedbushSet Price TargetBuy$30.00High
i
Rating by Michael Pachter at Wedbush
12/11/2017B. RileyReiterated RatingBuy$35.00Medium
i
11/20/2017B. RileyReiterated RatingBuy$35.00N/A
i
10/30/2017Barrington ResearchUpgradeMarket Perform ➝ Outperform$32.00N/A
i
Rating by J. Goss at Barrington Research
10/27/2017B. RileyReiterated RatingBuy$35.00N/A
i
10/27/2017WedbushReiterated RatingBuy$31.00N/A
i
10/27/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
i
10/23/2017Canaccord GenuitySet Price TargetBuy$32.00N/A
i
10/19/2017WedbushSet Price TargetBuy$29.00N/A
i
10/19/2017B. RileySet Price TargetBuy$35.00N/A
i
10/10/2017WedbushReiterated RatingBuy$29.00N/A
i
9/28/2017Credit Suisse GroupLower Price TargetNeutral$26.00 ➝ $25.00Low
i
9/17/2017Piper Jaffray CompaniesReiterated RatingBuy$28.00Low
i
8/18/2017Canaccord GenuitySet Price TargetBuy$33.00Low
i
8/3/2017JPMorgan Chase & Co.Reiterated RatingNeutral$27.00Low
i
8/1/2017B. RileyReiterated RatingBuy$35.00Medium
i
7/27/2017B. RileyReiterated RatingBuy$35.00High
i
7/27/2017WedbushReiterated RatingBuyHigh
i
7/21/2017Piper Jaffray CompaniesSet Price TargetBuy$35.00Low
i
7/20/2017WedbushReiterated RatingOutperform$35.00Low
i
7/12/2017Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by J. Goss at Barrington Research
7/10/2017B. RileyReiterated RatingBuy$43.50Low
i
7/7/2017MKM PartnersLower Price TargetBuy$40.00 ➝ $30.00Medium
i
7/5/2017B. RileyReiterated RatingBuy$43.50High
i
6/18/2017B. RileyReiterated RatingBuy$43.50Low
i
6/13/2017Piper Jaffray CompaniesReiterated RatingBuyMedium
i
6/13/2017Roth CapitalSet Price TargetBuy$33.00Medium
i
6/12/2017B. RileyReiterated RatingBuy$43.50High
i
6/8/2017Canaccord GenuitySet Price TargetBuy$33.00Low
i
6/7/2017BenchmarkDowngradeBuy ➝ HoldHigh
i
5/20/2017B. RileyReiterated RatingBuy$46.00Low
i
5/15/2017B. RileyReiterated RatingBuy$46.00High
i
5/12/2017WedbushReiterated RatingOutperform$39.00High
i
4/27/2017B. RileyReiterated RatingBuy$46.00Low
i
4/25/2017MKM PartnersReiterated RatingBuy$40.00Low
i
4/22/2017B. RileyReiterated RatingBuy$46.00Medium
i
4/21/2017WedbushLower Price TargetOutperform ➝ Outperform$41.50 ➝ $39.00Low
i
4/20/2017Roth CapitalSet Price TargetBuy$37.00Low
i
4/17/2017B. RileyReiterated RatingBuy$46.00High
i
4/10/2017Canaccord GenuityReiterated RatingBuy$39.00Low
i
3/2/2017B. RileyReiterated RatingBuy$46.00N/A
i
2/27/2017Canaccord GenuitySet Price TargetBuy$39.00N/A
i
2/26/2017Barrington ResearchReiterated RatingOutperform$40.00N/A
i
2/25/2017B. RileyReiterated RatingBuy$46.00N/A
i
2/24/2017WedbushReiterated RatingOutperform$41.50N/A
i
2/20/2017B. RileyReiterated RatingBuy$46.00N/A
i
2/18/2017Canaccord GenuitySet Price TargetBuy$39.00N/A
i
2/15/2017B. RileyReiterated RatingBuy$46.00N/A
i
2/14/2017WedbushReiterated RatingOutperform$41.50N/A
i
1/31/2017Credit Suisse GroupDowngradeOutperform ➝ Neutral$34.00N/A
i
1/18/2017MKM PartnersReiterated RatingBuy$40.00N/A
i
1/13/2017Canaccord GenuityReiterated RatingBuyN/A
i
1/8/2017B. RileyReiterated RatingBuy$46.00N/A
i
1/3/2017B. RileyReiterated RatingBuy$41.50 ➝ $46.00N/A
i
12/20/2016Canaccord GenuitySet Price TargetBuy$39.00N/A
i
12/20/2016Stifel NicolausReiterated RatingBuy$40.00N/A
i
12/9/2016B. RileyReiterated RatingBuy$41.50N/A
i
12/4/2016B. RileyReiterated RatingBuy$41.50N/A
i
11/29/2016B. RileyReiterated RatingBuy$42.50 ➝ $41.50N/A
i
11/16/2016B. RileyReiterated RatingBuy$42.50N/A
i
11/11/2016Credit Suisse GroupInitiated CoverageOutperform$42.00N/A
i
10/27/2016B. RileyReiterated RatingBuy$42.50N/A
i
10/23/2016WedbushSet Price TargetBuy$42.00N/A
i
10/21/2016B. RileyReiterated RatingBuy$42.50N/A
i
10/19/2016Canaccord GenuitySet Price TargetBuy$39.00N/A
i
10/18/2016MKM PartnersReiterated RatingBuy$40.00N/A
i
10/17/2016Roth CapitalSet Price TargetBuy$38.00N/A
i
10/17/2016WedbushReiterated RatingOutperform$41.50N/A
i
9/25/2016B. RileyReiterated RatingBuy$42.50N/A
i
9/21/2016WedbushReiterated RatingOutperform$41.50N/A
i
9/20/2016B. RileyReiterated RatingBuy$42.50N/A
i
9/14/2016MacquarieLower Price TargetOutperform$42.00 ➝ $41.00N/A
i
8/3/2016Stifel NicolausReiterated RatingBuy$45.00N/A
i
7/25/2016B. RileyReiterated RatingBuy$42.50N/A
i
7/24/2016WedbushReiterated RatingOutperform$40.00 ➝ $41.50N/A
i
7/24/2016Piper Jaffray CompaniesReiterated RatingOverweight$40.00 ➝ $45.00N/A
i
7/21/2016Credit Suisse GroupSet Price TargetBuy$42.00N/A
i
7/20/2016Roth CapitalInitiated CoverageBuy$38.00N/A
i
Rating by D. Aftahi at Roth Capital
7/19/2016Canaccord GenuityReiterated RatingBuyN/A
i
7/18/2016B. RileyReiterated RatingBuy$40.00N/A
i
7/13/2016B. RileyReiterated RatingBuy$40.00N/A
i
7/12/2016WedbushReiterated RatingOutperform$40.00N/A
i
6/23/2016Stifel NicolausReiterated RatingBuy$45.00N/A
i
6/22/2016Canaccord GenuityReiterated RatingBuyN/A
i
6/22/2016Credit Suisse GroupReiterated RatingBuyN/A
i
6/22/2016BenchmarkReiterated RatingBuyN/A
i
6/13/2016Stifel NicolausReiterated RatingBuy$45.00N/A
i
6/12/2016B. RileyReiterated RatingBuy$40.00N/A
i
6/7/2016B. RileyReiterated RatingBuy$45.00 ➝ $40.00N/A
i
5/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$45.00N/A
i
5/25/2016MacquarieReiterated RatingOutperform$43.00N/A
i
5/25/2016B. RileyReiterated RatingBuy$45.00N/A
i
Rating by Eric Wold at B. Riley
5/24/2016MKM PartnersReiterated RatingBuy$40.00N/A
i
Rating by Eric Handler at MKM Partners
5/24/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Robert Peters at Credit Suisse Group AG
5/20/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Aravinda Galappatthige at Canaccord Genuity
5/12/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Aravinda Galappatthige at Canaccord Genuity
(Data available from 5/10/2016 forward)
IMAX logo
IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company worldwide. It offers cinematic solution comprising proprietary software, theater architecture, intellectual property, and specialized equipment. The company offers IMAX Digital Re-Mastering (DMR), a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of motion picture films for projection on IMAX screens; IMAX theater systems to exhibitor customers through sales, leases, and joint revenue sharing arrangements; digital projection systems; a digital theater control systems; and a digital audio systems. It also provides proactive and emergency maintenance services to the IMAX network; licenses film content and distributes large-format documentary films; film post-production and quality control services for large-format films, and digital post-production services; owns and operates IMAX theaters; and rents 2D and 3D large-format film and digital cameras, as well as offers production advice and technical assistance services to documentary and Hollywood filmmakers. The company markets its theater systems through a direct sales force and marketing staff to science and natural history museums, zoos, aquaria, and other educational and cultural centers, as well as theme parks, private home theaters, tourist destination sites, fairs, and expositions. It owns or otherwise has rights to trademarks and trade names, which include IMAX, IMAX Dome, IMAX 3D, IMAX 3D Dome, Experience It in IMAX, The IMAX Experience, An IMAX Experience, An IMAX 3D Experience, IMAX DMR, DMR, IMAX nXos, and Films To The Fullest. As of December 31, 2020, the company had a network of 1,650 IMAX theater systems comprising 1,562 commercial multiplexes, 12 commercial destinations, and 76 institutional facilities operating in 81 countries and territories. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $21.04
$20.96
$21.30

50 Day Range

MA: $21.09
$19.77
$22.43

52 Week Range

Now: $21.04
$10.31
$25.05

Volume

9,649 shs

Average Volume

963,862 shs

Market Capitalization

$1.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of IMAX?

The following Wall Street analysts have issued research reports on IMAX in the last twelve months: B. Riley, Barrington Research, Benchmark Co., Canaccord Genuity, Macquarie, MKM Partners, The Goldman Sachs Group, Inc., TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for IMAX.

What is the current price target for IMAX?

8 Wall Street analysts have set twelve-month price targets for IMAX in the last year. Their average twelve-month price target is $24.05, suggesting a possible upside of 14.4%. Macquarie has the highest price target set, predicting IMAX will reach $30.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $14.50 for IMAX in the next year.
View the latest price targets for IMAX.

What is the current consensus analyst rating for IMAX?

IMAX currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMAX will outperform the market and that investors should add to their positions of IMAX.
View the latest ratings for IMAX.

What other companies compete with IMAX?

Other companies that are similar to IMAX include GoPro, Eastman Kodak, Ballantyne Strong, IKONICS and ImageWorks.

How do I contact IMAX's investor relations team?

IMAX's physical mailing address is 2525 Speakman Drive, Mississauga A6, L5K 1B1. The company's listed phone number is (905) 403-6500 and its investor relations email address is [email protected] The official website for IMAX is www.imax.com.